Adesh Kaul

FDA Approves Basilea’s ZEVTERA® for Severe Bacterial Infections, Including Pediatric Use

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) for…

1 month ago

Basilea Pharmaceutica Reports Strong H1 2023 Financial Results and Increases Full-Year Guidance

(IN BRIEF) Basilea Pharmaceutica Ltd, a biopharmaceutical company specializing in severe bacterial and fungal infection treatments, has announced robust financial…

9 months ago

Basilea Pharmaceutica Ltd secures non-dilutive refinancing from funds managed by Athyrium Capital Management, LP for its outstanding 2022 convertible bonds

Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX:…

2 years ago

Basilea Pharmaceutica Ltd obtient un refinancement non dilutif auprès de fonds gérés par Athyrium Capital Management, LP pour ses obligations convertibles 2022 en circulation

Annonce ad hoc conformément à l'art. 53LR (COMMUNIQUÉ DE PRESSE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX :…

2 years ago

Adesh Kaul will join Basilea Pharmaceutica’s Management Committee as Chief Corporate Development Officer

BASEL, 05-Mar-2018 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that Adesh Kaul will join Basilea's Management Committee as…

6 years ago